Validity of Check Point Inhibitor (PD-1 and PD-L1) in Diagnosis of Gastric Adenocarcinoma Using Modified Tissue Elisa | [Pakistan Journal of Medical and Health Sciences • 2022]

Author(s):

1. HIND H. AL-AMMIRI: Microbiology department, collage of Vet. Medicine, Baghdad University

2. MOHAMMED M. MOHAMMED: Microbiology department, collage of Vet. Medicine, Baghdad University

3. ALI ABDUL HUSSEIN: Microbiology department, collage of Medicine, Baghdad University

4. AMEER DHAHIR HAMEEDI: Microbiology department, collage of Medicine, Baghdad University

Abstract:

Background: Checkpoint inhibitors (PD-1, PD-L1) are revolutionizing the oncology disease management process. Despite the fact that gastric cancer is a common malignancy with a poor prognosis, relatively little attention has been drawn and attracted to the treatment and diagnosis of this disease by using checkpoint inhibitor. James P. Allison and Tasuku Honjo were awarded the the Nobel Prize in Physiology and Medicine for their developments in fundamental science enabling checkpoint inhibitor therapies. Checkpoint inhibitor overexpression has been related to gastric cancer progression and clues for developing therapeutic goals as well as may provide diagnostic markers for gastric cancer. Aims: The aims of this study are firstly to detection of Checkpoint Inhibitors (PD-1, PD-L1) as novel diagnostics and prognostics markers first time in the world. Secondly, to investigate the validity of using (a modified tissue ELISA method) as a rapid, sensitive, low cost and specific diagnostic method in patients with gastric cancer. Patients and methods: Thirty gastric cancer patients were among patients who attending the Histopathology section -GIT hospital and Histopathology department- Teaching laboratories/ medical city teaching complex Baghdad / Ministry of Health, during the period from August 2020 to April 2021. Another 30 patients diagnosed with benign tumor, In addition, 30 apparently healthy people were chosen as a healthy control group. For these three groups, PD-1, PD-L1, using tissue ELISA technique was carried out. Results: The current study showed that the mean values of PD-1 in tissues of gastric cancer patients (133.413±53.126) was significantly higher (P=0.0001) in it in comparison to both benign tumor group (29.905±12.634) and control healthy group (21.775±12.489); for PD-L1 that the mean values of PD-L1 in tissues of gastric cancer patients (151.175±47.641) was significantly higher (P=0.0001) in it in comparison to both benign tumor group (72.565±9.945) and control healthy group (82.102±12.642); using receiver operating characteristic curve (ROC) area, which showed that area under the curve for PD-1 was (1.000) (p value 0.0001), while area under the curve for PDL-1 was (0.913) (p value 0.0001) and The cut off value for PD-1 associated with highest sensitivity and specificity (100%) was 40.2 ng/ml. The cut off value for PDL-1 associated with sensitivity (80%) and specificity (80%) was 51.6ng/ml. Conclusions: The present study showed that Checkpoint inhibitors (PD-1, PD-L1) values were significantly higher in patients affect with malignant gastric adenocarcinoma which may check a possible role of this marker in the progressing of the disease, furthermore the maximum sensitivity obtained from Checkpoint inhibitors (PD-1, PD-L1) was by using a cut off values equal to (40.2 ng/ml; 51.6 ng/ml) respectively. Therefore, Checkpoint inhibitors (PD-1, PD-L1) may be promising diagnostic tools especially at early stages and among patients at in promotion risk.

Page(s): 622-624

DOI: 10.53350/pjmhs22166622

Published: Journal: Pakistan Journal of Medical and Health Sciences, Volume: 16, Issue: 06, Year: 2022

Keywords:

gastric cancer , PDL1 , Checkpoint inhibitors PD1

References:

[1] Werner M.,Becker K. F.,Hofler H. .2001 .Gastric adenocarcinoma: pathomorphology and molecular pathology. J. Cancer Res. Clin. Oncol, 127 : 207-216.

[2] Kim B.,Bang S.,Lee S. .2003 .. Expression Profiling and SubtypeSpecific Expression of Stomach Cancer. Cancer Res, 63 : 8248-8255.

[3] SYN N. L. T.,MICHELE W L; MOK,TONY S K; SOO .2017 .ROSS A. Denovo and acquired resistance to immune checkpoint targeting. The Lancet Oncology, 18 : e731-e741.

[4] L. M. ,SAGE ,SHARPE P. T.,A. H.. P. T. .2010 .The PD‐1 pathway in tolerance and autoimmunity. Immunological reviews, 236 : 219-242.

[5] FIFE BT .2011 .The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Annals of the New York Academy of Sciences, 1217 : 45-59.

[6] Kalim M.,Khan Iqbal,Zhan M. S.,J.. M. S. .2020 .Programmed cell death ligand‐1: A dynamic immune checkpoint in cancer therapy. Chemical biology & drug design, 95(6) : 552-566.

[7] SAID E. A.,DUPUY F. P.,TRAUTMANN L.,SHI Y.,EL-FAR M.,HILL M.,B. J. M.,NOTO M.,A. M.,ANCUTA M.,PERETZ P.,Programmed P. .2010 .-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nature medicine, 16 : 452-459.

[8] KARWACZ K,MACDONALD B. C.,D B. C.,BENNETT F,COLLINS CL,M CL .2011 .ESCORS D. PD-L1 co-stimulation contributes to ligandinduced T cell receptor down-modulation on CD8+ T cells. EMBO Molecular Medicine, 3 : 581-92.

[9] Zalba S.,Contreras-Sandoval A. M.,Martisova E.,Debets R.,Smerdou C.,Garrido M. J.. .2020 .Quantification of pharmacokinetic profiles of pd-1/pd-l1 antibodies by validated elisas. Pharmaceutics, 12(6) : 595.

[10] Chiu Y. M.,Tsai C. L.,Kao J. T.,Hsieh C. T.,Shieh D. C.,Lee Y. J.,Wu Y. Y.. .2018 .PD-1 and PD-L1 up-regulation promotes T-cell apoptosis in gastric adenocarcinoma. Anticancer research, 38(4) : 2069-2078.

[11] Gao Q,Wang XY,Qiu SJ,Yamato I,Sho M,Nakajima Y,Zhou J,Li BZ,Shi YH,Xiao YS,Xu Y,Fan J .2009 .Overexpression of pd-l1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res, 15(3) : 971-979.

[12] Dai L.,Huang Z.,Li W.. .2021 .Analysis of the PD-1 ligands among gastrointestinal cancer patients: focus on cancer immunity. Frontiers in oncology., 11 : 525.

[13] Park JJ,Omiya R,Matsumura Y .2010 .B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T cell tolerance. Blood, 116 : 1291-8.

[14] Zheng Z.,Bu Z.,Liu X.,Zhang L.,Li Z.,Wu A.,Ji J.. .2014 .Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chinese Journal of Cancer Research, 26(1) : 104.

[15] WU C.,ZHU Y.,JIANG Y.,ZHAO J.,XU J.,N.. J. .2006 .Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta histochemica, 108 : 19-24.

Citations

Downloads

Views